This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Day One Biopharmaceuticals (DAWN) Aandelenoverzicht
Day One Biopharmaceuticals, Inc. is een biofarmaceutisch bedrijf in een commerciële fase dat zich bezighoudt met de identificatie, ontwikkeling en commercialisering van geneesmiddelen voor ziekten bij kinderen en volwassenen, met gelijke intensiteit in de Verenigde Staten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 5/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
DAWN Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Day One Biopharmaceuticals, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$21.53 |
| 52 Week Hoogtepunt | US$21.53 |
| 52 Week Laag | US$5.64 |
| Bèta | -1.75 |
| 1 maand verandering | 0.61% |
| 3 maanden verandering | 80.17% |
| 1 Jaar Verandering | 178.17% |
| 3 jaar verandering | 73.63% |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | -16.84% |
Recent nieuws en updates
Narratiefupdate • Apr 13
DAWN: Servier Cash Offer Will Define Deal Outcome And Future Pipeline Path
Analysts have reset their Day One Biopharmaceuticals price targets to $21.50, generally aligning with Servier's agreed $21.50 per share cash acquisition price. They are also shifting ratings to more neutral stances, as upside potential is now seen as capped by the deal terms.Narratiefupdate • Mar 29
DAWN: Servier Cash Offer Will Frame Deal Completion And Pipeline Optionality
Analysts have reset their price targets on Day One Biopharmaceuticals to $21.50, a move of up to $3.00 from prior estimates. They are aligning their models with the agreed $21.50 per share cash acquisition by Servier and see limited scope for additional upside from standalone growth assumptions.Narratiefupdate • Mar 15
DAWN: Servier Cash Offer Will Define Future Upside And Downside Potential
The analyst price target for Day One Biopharmaceuticals has shifted from $22.25 to $21.50, with analysts aligning their views to the agreed $21.50 per share cash acquisition price from Servier and adjusting their assumptions around revenue growth, profit margins, discount rate, and future P/E accordingly. Analyst Commentary Following the Servier agreement, Street research has largely converged around the US$21.50 cash offer, with multiple firms cutting ratings to Neutral or Hold and aligning price targets with the acquisition price.Recent updates
Narratiefupdate • Apr 13
DAWN: Servier Cash Offer Will Define Deal Outcome And Future Pipeline Path
Analysts have reset their Day One Biopharmaceuticals price targets to $21.50, generally aligning with Servier's agreed $21.50 per share cash acquisition price. They are also shifting ratings to more neutral stances, as upside potential is now seen as capped by the deal terms.Narratiefupdate • Mar 29
DAWN: Servier Cash Offer Will Frame Deal Completion And Pipeline Optionality
Analysts have reset their price targets on Day One Biopharmaceuticals to $21.50, a move of up to $3.00 from prior estimates. They are aligning their models with the agreed $21.50 per share cash acquisition by Servier and see limited scope for additional upside from standalone growth assumptions.Narratiefupdate • Mar 15
DAWN: Servier Cash Offer Will Define Future Upside And Downside Potential
The analyst price target for Day One Biopharmaceuticals has shifted from $22.25 to $21.50, with analysts aligning their views to the agreed $21.50 per share cash acquisition price from Servier and adjusting their assumptions around revenue growth, profit margins, discount rate, and future P/E accordingly. Analyst Commentary Following the Servier agreement, Street research has largely converged around the US$21.50 cash offer, with multiple firms cutting ratings to Neutral or Hold and aligning price targets with the acquisition price.
Narratiefupdate • Mar 01
DAWN: Ojemda Franchise And Mersana Integration Will Recast Future Earnings Power
Analysts nudged their price target on Day One Biopharmaceuticals up by $1 to $30, reflecting updated assumptions around revenue growth, profitability, and future P/E, now that recent Street research has incorporated both the latest quarterly results and ongoing Ojemda development plans. Analyst Commentary Bullish analysts are framing the latest price target move to $30 as part of a broader, constructive view on Day One Biopharmaceuticals, grounded in updated revenue, profitability, and P/E assumptions around the Ojemda franchise and recent quarterly results.Seeking Alpha • Feb 27
Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead
Summary Day One Biopharmaceuticals, Inc.'s Q4 '25 came with net product revenues of $52.8M, up 36% from the prior quarter. DAWN's 2026 guidance for U.S. net product revenues of $225M-$250M implies 50% growth over 2025 at the midpoint of that guidance. Key catalysts include clinical readouts from Emi-Le and DAY-301 in 2026. A readout from FIREFLY-2 could come in mid-2027. Read the full article on Seeking Alpha
Narratiefupdate • Feb 15
DAWN: Future Cash Flows From Mersana Acquisition Will Drive Upside Potential
Analysts raised their fair value estimate for Day One Biopharmaceuticals by $1 to $17.00, citing updated assumptions that combine higher revenue expectations, a higher future P/E, and a slightly higher discount rate. Analyst Commentary Recent Street research on Day One Biopharmaceuticals reflects a mix of optimism about the company’s potential and caution about execution risks and valuation.Narratiefupdate • Feb 01
DAWN: Mersana Acquisition Will Recast Pipeline Risk Profile And Future Earnings Power
Narrative Update: Day One Biopharmaceuticals Analysts have adjusted their price target on Day One Biopharmaceuticals from US$27 to US$29, reflecting updated views on the Mersana acquisition, revised assumptions for future revenue growth and profit margins, and a higher future P/E multiple, even as some recent research has featured lower individual price targets. Analyst Commentary Recent Street research around Day One Biopharmaceuticals has centered on the acquisition of Mersana Therapeutics and how that deal reshapes the company’s pipeline, risk profile, and potential long term earnings power.Analyseartikel • Jan 21
Optimistic Investors Push Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Up 31% But Growth Is Lacking
Despite an already strong run, Day One Biopharmaceuticals, Inc. ( NASDAQ:DAWN ) shares have been powering on, with a...Narratiefupdate • Jan 08
DAWN: Mersana Acquisition And OJEMDA Durability Data Will Reshape Pipeline Risk Profile
Analysts have adjusted their price target on Day One Biopharmaceuticals from US$34.00 to US$27.00, citing updated assumptions on growth, margins and future P/E, along with support for the recently announced, higher cost acquisition of Mersana Therapeutics as a way to diversify the pipeline beyond OJEMDA. Analyst Commentary Bullish analysts are framing the Mersana deal as a sign that Day One is willing to pay up to secure assets that fit tightly with its focus on targeted oncology, even if the acquisition cost of up to US$285 million looks full on headline terms.Narratiefupdate • Dec 23
DAWN: Mersana Deal Will Diversify ADC Platform And Support Future Upside
Analysts nudged their price target on Day One Biopharmaceuticals slightly higher to $22.25 per share, citing cautious optimism that the $285 million Mersana acquisition could diversify the pipeline beyond OJEMDA and enhance long term growth prospects despite its premium valuation. Analyst Commentary Bullish Takeaways Bullish analysts view the acquisition of Mersana as a strategic way to add a second antibody drug conjugate, Emi Le, alongside PTK7.Analyseartikel • Dec 19
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Narratiefupdate • Dec 09
DAWN: Mersana Acquisition Will Diversify ADC Pipeline And Support Long Term Upside
Analysts slightly raised their price target for Day One Biopharmaceuticals to $22.25 per share, citing the strategically bold, though expensive, acquisition of Mersana Therapeutics as a catalyst for pipeline diversification beyond OJEMDA and as a potential source of long term value. Analyst Commentary Analyst reactions to the Mersana deal highlight a mix of strategic enthusiasm and execution risk, with many viewing the transaction as a meaningful but high stakes swing for Day One's long term growth profile and valuation.Narratiefupdate • Nov 25
DAWN: Acquisition of ADC Candidate Will Broaden Pipeline and Patient Reach
Analysts have lowered their price target for Day One Biopharmaceuticals from $24.25 to $22.25. They cited uncertainty over the recent $285 million Mersana acquisition, despite noting improved profit margin and revenue projections.Analyseartikel • Nov 08
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Fly 29% But Investors Aren't Buying For Growth
Day One Biopharmaceuticals, Inc. ( NASDAQ:DAWN ) shares have continued their recent momentum with a 29% gain in the...Analyseartikel • Nov 07
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Day One Biopharmaceuticals, Inc. ( NASDAQ:DAWN ) just released its latest quarterly results and things are looking...Analyseartikel • Sep 06
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Held Back By Insufficient Growth Even After Shares Climb 30%
Day One Biopharmaceuticals, Inc. ( NASDAQ:DAWN ) shareholders would be excited to see that the share price has had a...Narratiefupdate • Aug 07
Expanded Clinical Indications And European Approvals Will Shape Future Oncology
Despite a substantially improved net profit margin and a lower future P/E ratio indicating enhanced profitability and valuation, the consensus analyst price target for Day One Biopharmaceuticals has been reduced from $26.25 to $24.00. Valuation Changes Summary of Valuation Changes for Day One Biopharmaceuticals The Consensus Analyst Price Target has fallen from $26.25 to $24.00.Analyseartikel • Jul 18
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Nieuw narratief • Apr 29
FDA Approval And Ipsen Licensing Will Expand Pediatric Treatment Options
FDA approval and the launch of OJEMDA boost long-term revenue growth, addressing unmet medical needs and strong market uptake in pediatric glioma.Seeking Alpha • Feb 03
Day One Biopharmaceuticals: A Successful Launch In Pediatric Cancer
Summary Day One Biopharma's OJEMDA received FDA accelerated approval in 2024 for relapsed/refractory BRAF-altered pediatric low-grade glioma, with strong Phase 2 trial results and ongoing Phase 3 studies. Despite OJEMDA's 2024 sales reaching $57.2 million, market concerns persist due to its small patient population and competition from Novartis' BRAF-targeted therapy. Day One's pipeline includes DAY301, targeting PTK7 in solid tumors, but its early-stage development suggests FDA approval is years away. Given current market conditions and future catalysts, I rate Day One Biopharma as a Hold, with potential for a more bullish outlook based on revenue growth and pipeline progress. Read the full article on Seeking AlphaSeeking Alpha • Jan 07
Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)
Summary Day One Biopharmaceuticals focuses on pediatric cancer treatments, with a promising pipeline including tovorafenib and other targeted therapies. The stock has experienced a bearish trend but has significant upside potential, with Wall Street targeting a 190% increase. Strong financial position with $558.4M in cash and a cash runway of over 3 years significantly reducing the dilution risk. Potential peak sales of $800M-$1B and a valuation upside of 215%-294%, making DAWN a compelling investment opportunity. Read the full article on Seeking AlphaAnalyseartikel • Nov 04
Forecast: Analysts Think Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Business Prospects Have Improved Drastically
Celebrations may be in order for Day One Biopharmaceuticals, Inc. ( NASDAQ:DAWN ) shareholders, with the analysts...Analyseartikel • Jul 12
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Seeking Alpha • Jul 07
Day One Biopharmaceuticals: Still Uncertainty After FDA Approval
Summary Today, we circle back to Day One Biopharmaceuticals as the company's stock has dropped some even after its first FDA approval in late April. Analysts are optimistic about Day One Biopharmaceuticals, with numerous buy ratings and price targets ranging from $33 to $40 a share. The stock currently trades for less than $14/share. Despite the FDA approval, there is still some uncertainty as there are several moving parts to this story. An updated analysis follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Apr 24
Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
Summary Day One Biopharmaceuticals, Inc. secured accelerated approval for its lead drug tovorafenib yesterday in pediatric brain cancer. The drug will be marketed and sold as Ojemda. Ojemda will be able to address a larger patient population that Novartis' currently approved Mekinist - perhaps 2-3k patients per annum. That opens up a market opportunity of ~$1bn, and peak revenue opportunity of $500 - $600m, I estimate. As a loss-making company that must complete a post-marketing study of Ojemda before full approval is granted, current market cap valuation of ~$1.4bn seems fair. Read the full article on Seeking AlphaAnalyseartikel • Mar 18
We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Feb 01
Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Summary Day One Biopharmaceuticals is a leader in pediatric oncology, with a focus on addressing the unmet needs of pediatric cancer patients. The company has a strong financial position, with enough cash to fund operations through 2026, and is progressing through clinical trials with promising results. Day One's lead product candidate, tovorafenib, has the potential to redefine the standard of care for pediatric low-grade glioma, pending regulatory approval. Read the full article on Seeking AlphaAnalyseartikel • Dec 04
We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyseartikel • Jun 19
We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Rendement voor aandeelhouders
| DAWN | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 0.3% | 1.2% | 1.6% |
| 1Y | 178.2% | 35.9% | 28.5% |
Rendement versus industrie: DAWN overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 35.9 % opleverde.
Rendement versus markt: DAWN overtrof de US markt, die het afgelopen jaar een rendement opleverde van 28.5 %.
Prijsvolatiliteit
| DAWN volatility | |
|---|---|
| DAWN Average Weekly Movement | 21.2% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stabiele aandelenkoers: De aandelenkoers van DAWN is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van DAWN is het afgelopen jaar gestegen van 14% naar 21%.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2018 | 178 | Jeremy Bender | dayonebio.com |
Day One Biopharmaceuticals, Inc, een biofarmaceutisch bedrijf in commerciële fase, houdt zich bezig met de identificatie, ontwikkeling en commercialisering van geneesmiddelen voor ziekten bij kinderen en volwassenen met gelijke intensiteit in de Verenigde Staten. De belangrijkste productkandidaat van het bedrijf is tovorafenib, een orale en hersenpenetrerende type II snel versnellende kinaseremmer voor fibrosarcomen die zich in Fase II van het klinisch onderzoek bevindt voor pediatrische patiënten met recidief of refractair laaggradig glioom. Het ontwikkelt ook DAY301, een op PTK7 gerichte ADC die bestaat uit een nieuw gehumaniseerd anti-PTK7 immunoglobuline G1 monoklonaal antilichaam geconjugeerd met een topoisomerase I remmer via een zeer stabiele en hydrofiele gemodificeerde valine-alanine (VA) splitsbare linker voor de behandeling van patiënten met vergevorderde vaste tumoren; en Emi-Le, een antilichaam-drugconjugaat gericht tegen B7-H4 geconjugeerd aan een auristatine anti-tubuline payload als onderdeel van een gepatenteerd linker-payload platform ontwikkeld door Mersana Therapeutics dat zich in Fase 1 klinische studie bevindt voor de behandeling van borstkanker, eierstokkanker, endometriumkanker en adenoïd cystisch carcinoom (ACC).
Day One Biopharmaceuticals, Inc. Samenvatting
| DAWN fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$2.22b |
| Inkomsten(TTM) | -US$107.32m |
| Inkomsten(TTM) | US$158.18m |
14.1x
P/S-verhouding-20.7x
Koers/WinstverhoudingIs DAWN overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| DAWN resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$158.18m |
| Kosten van inkomsten | US$17.21m |
| Brutowinst | US$140.97m |
| Overige uitgaven | US$248.29m |
| Inkomsten | -US$107.32m |
Laatst gerapporteerde inkomsten
Dec 31, 2025
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -1.04 |
| Brutomarge | 89.12% |
| Nettowinstmarge | -67.85% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde DAWN op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/04/25 17:00 |
| Aandelenkoers aan het einde van de dag | 2026/04/22 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Day One Biopharmaceuticals, Inc. wordt gevolgd door 5 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Naureen Quibria | Capital One Securities, Inc. |
| Andrea Newkirk | Goldman Sachs |
| Andrea Newkirk | Goldman Sachs |